Table 8.

Limitations of treatment success in first-line ER+, HER2- mBC patients - aromatase inhibitors only – from physician survey (n = 103)

	Not at all substantial		Not at all substantial		Moderately substantial		Substantial		Very substantial
	n	%	n	%	n	%	n	%	n	%
Efficacy	4	3.9%	8	7.8%	43	41.8%	25	24.3%	23	22.3%
Safety/Tolerability	16	15.5%	24	23.3%	23	22.3%	29	28.2%	11	10.7%
Drug resistance	1	1.0%	12	11.7%	42	40.8%	41	39.8%	7	6.8%
Adherence	13	12.6%	23	22.3%	33	32.0%	24	23.3%	10	9.7%
Financial cost of treatments	14	13.6%	24	23.3%	28	27.2%	28	27.2%	9	8.7%

mBC metastatic breast cancer